The COVID-19 pandemic has shown the critical importance of vaccination strategies to protect vulnerable populations, including pregnant women, from severe disease and its lingering consequences. Although growing evidence demonstrates that COVID-19 vaccines are both safe and highly beneficial during pregnancy, vaccine hesitancy among pregnant women persists, partly fueled by the persistent, decade-old "urban myth" linking vaccination during pregnancy to neuropsychiatric disorders in children. Here, we used a mouse model of passive immunization with severe acute respiratory syndrome coronavirus 2 spike neutralizing monoclonal antibodies (SaCoV-AB) to determine the effects of gestational COVID-19 vaccination on key pregnancy outcomes, maternal and offspring health, and behavior. We show that at a higher SaCoV-AB dosage, maternal immune response is reflected in elevated TNF-α levels in maternal serum, but not in the placenta or the fetal brain, with no effect on pregnancy outcomes. We report no consequences for postpartum maternal care behavior and neonatal communication signatures. Behavioral assessment of adult female and male offspring after maternal SaCoV-AB treatment revealed no differences in phenotypes relevant to neurodevelopmental disorders. Our findings indicate that in a preclinical model, passive immunization with SaCoV-AB during pregnancy is well-tolerated, with no discernable impact on maternal or offspring health and behavior.

01 Mar 2025·Cancer Medicine

SARS‐CoV‐2 Infection Aggravates Physical and Mental Health in Cancer Patients Compared to Co‐Living Individuals

Article

Author: Zhao, Wujie ; Tie, Yanqing ; Jia, Xiaojing ; Jia, Yitao ; Wang, Bin ; Zhi, Jie ; Liu, Jiayao ; Li, Na

ABSTRACTIntroductionCancer patients are particularly vulnerable to the psychological sequels of COVID‐19 due to their immunocompromised state and the disruptions to their regular oncological care. There is limited research comparing the effects of SARS‐CoV‐2 on cancer patients and their co‐living individuals. This study aims to explore the similarities and differences in physical and psychological outcomes between these two groups, with a 1‐year follow‐up to assess long‐term effects.MethodsThis retrospective observational study was conducted between January and February 2023. A total of 107 participants were included: 72 cancer patients and 35 co‐living individuals, all diagnosed with COVID‐19. Clinical and laboratory data were collected. Depression, anxiety, and fatigue were assessed at two timepoints: shortly after COVID‐19 diagnosis and 1 year later.ResultsCancer patients exhibited higher rates of gastrointestinal symptoms, such as diarrhea (20.83% vs. 5.71%, p = 0.045), which were associated with increased anxiety and depression (p < 0.05). Advanced‐stage cancer (p < 0.01) and lack of vaccination (p < 0.01) correlated with worse psychological outcomes. Female cancer patients reported higher depression scores (p < 0.05). Laboratory findings indicated higher neutrophil percentages (p < 0.001), fibrinogen (p < 0.001), and D‐dimer levels (p = 0.015) in cancer patients, signaling a higher risk of inflammation and thrombosis. Both groups showed improvements in depression and fatigue over the 1‐year follow‐up, but cancer patients continued to report greater psychological distress (p < 0.001) and fatigue (p = 0.024).ConclusionCancer patients infected with COVID‐19 experienced more severe physical and psychological symptoms compared to their co‐living individuals, with persistent differences 1 year after infection.Trial RegistrationChiCTR2300067577

17 Feb 2025·Journal of Chemotherapy

Antiviral combination regimens as rescue therapy in immunocompromised hosts with persistent COVID-19

Article

Author: Morettini, Alessandro ; Barbiero, Anna ; Menicacci, Lorenzo ; Spinicci, Michele ; Rossolini, Gian Maria ; Manciulli, Tommaso ; Paci, Lorenzo ; Antonello, Roberta Maria ; Di Lauria, Nicoletta ; Sordi, Benedetta ; Tomassetti, Sara ; Zammarchi, Lorenzo ; Ducci, Filippo ; Marangoni, Davide ; Bartoloni, Alessandro ; Graziani, Lucia

The management of severe/prolonged SARS-CoV-2 infections in immunocompromised hosts is still challenging. We describe nine patients with hematologic malignancies with a history of unsuccessful SARS-CoV-2 treatment receiving antiviral combination treatment for persistent infection at a tertiary hospital in central Italy (University Hospital of Careggi, Florence). Combination treatments consisted of nirmatrelvir/ritonavir plus molnupiravir (n = 4), nirmatrelvir/ritonavir plus remdesivir (n = 4) or remdesivir plus molnupiravir (n = 1) for 10 days, in some cases associated with sotrovimab. Combinations were generally well tolerated. One patient obtained viral clearance but died due to the underlying disease. In eight cases, clinical and virological success was confirmed by radiological follow-up. Antivirals combination is likely to become a mainstay in the future management of COVID-19 among immunocompromised patients, but knowledge in this field is still very limited and prospective studies on larger cohorts are urgently warranted.

100 Deals associated with SARS-CoV-2 (Vicebio)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Preclinical	United Kingdom	Vicebio Ltd.	04 Sep 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

SARS-CoV-2 (Vicebio)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation